Differential gene expression triggered by highly cytotoxic α-Emitter-immunoconjugates in gastric cancer cells
- 13 January 2009
- journal article
- Published by Springer Science and Business Media LLC in Investigational New Drugs
- Vol. 28 (1), 49-60
- https://doi.org/10.1007/s10637-008-9214-4
Abstract
Immunoconjugates composed of the α-emitter 213Bi and the monoclonal antibody d9MAb specifically target HSC45-M2 gastric cancer cells expressing mutant d9-E-cadherin. These conjugates efficiently killed tumor cells in a nude mouse peritoneal carcinomatosis model. To elucidate the molecular responses of HSC45-M2 cells to α-emitter irradiation, whole genome gene expression profiling was performed. For that purpose HSC45-M2 cells were incubated with lethal doses of 213Bi-d9MAb. RNA was isolated at 6, 24 and 48 h after irradiation, transcribed into cDNA and hybridized to whole genome microarrays. Results of microarray analysis were validated using RTQ-PCR showing correspondence of approximately 90%. Following incubation with 213Bi-d9MAb, 682-1125 genes showed upregulation and 666-1278 genes showed downregulation at one time point, each. Eight genes appeared upregulated and 12 genes downregulated throughout. Molecular functions and biological processes of differentially expressed genes were categorized according to the PANTHER database. Following 213Bi-d9MAb irradiation also a time-dependent shift in terms of overrepresentation of biological processes was observed. Among the genes showing continuous upregulation, COL4A2, NEDD9 and C3 have not been associated with the cellular response to high LET radiation so far. The same holds true for WWP2, RFX3, HIST4H4 and JADE1 that showed continuous downregulation. According to PANTHER, three of the consistently upregulated (ITM2C, FLJ11000, MSMB) and downregulated (HCG9, GAS2L3, FLJ21439) genes, respectively, have not been associated with any biological process or molecular function so far. Thus, these findings revealed interesting new targets for selective elimination of tumor cells and new insights regarding response of tumor cells to α-emitter exposure.Keywords
This publication has 56 references indexed in Scilit:
- Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6Journal of Nuclear Medicine, 2007
- Targeted α-therapy: past, present, future?Dalton Transactions, 2007
- Wwp2-Mediated Ubiquitination of the RNA Polymerase II Large Subunit in Mouse Embryonic Pluripotent Stem CellsMolecular and Cellular Biology, 2007
- SRY-Related HMG Box 9 Regulates the Expression of Col4a2 through Transactivating Its Enhancer Element in Mesangial CellsThe American Journal of Pathology, 2007
- Structural transitions of complement component C3 and its activation productsProceedings of the National Academy of Sciences of the United States of America, 2006
- Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular targetProceedings of the National Academy of Sciences of the United States of America, 2006
- Loss of Ubr2, an E3 ubiquitin ligase, leads to chromosome fragility and impaired homologous recombinational repairMutation research. Reviews in mutation research, 2006
- Gene Silencing of CENP-E by Small Interfering RNA in HeLa Cells Leads to Missegregation of Chromosomes after a Mitotic DelayMolecular Biology of the Cell, 2004
- Reasons to reconsider the significance of apoptosis for cancer therapyInternational Journal of Radiation Biology, 2003
- Expression of cytoskeletal and matrix genes following exposure to ionizing radiation: dose-rate effects and protein synthesis requirementsCancer Letters, 1995